Eli Lilly and Company (NYSE: LLY) saw its shares climb approximately 2.9% on Monday after the United Kingdom became the first European nation to grant regulatory approval for Foundayo, the company's oral tablet designed for weight management and type 2 diabetes. The stock was trading around $1,220 by 14:19 EDT, pushing the pharmaceutical giant's market capitalization to roughly $1.09 trillion.
The approval, granted by the Medicines and Healthcare products Regulatory Agency (MHRA), marks a significant milestone for Lilly's expanding metabolic portfolio. However, the authorization does not automatically translate into availability on the UK's National Health Service (NHS), nor does it extend to the broader European Union. Lilly has yet to disclose a UK pricing strategy or a launch timeline, leaving the path for private-market availability uncertain.
The market's response was substantial, with the increase in equity value estimated at around $30.7 billion—a figure derived from the company's market cap and the percentage move. To put that in perspective, Foundayo generated $98 million in sales during the second quarter, its first full quarter since launch. This means Monday's gain was roughly 313 times the pill's quarterly revenue, underscoring the market's optimism about its long-term potential, even though the product remains in its early stages.
Foundayo's sales are still modest compared to Lilly's established injectable treatments. Mounjaro brought in $9.943 billion in Q2, while Zepbound contributed $4.928 billion. Lilly's total quarterly revenue reached $22.974 billion, a 48% year-over-year increase. The company has also raised its full-year 2026 revenue guidance to $85 billion–$87 billion, up from a previous range of $82 billion–$85 billion.
The MHRA's approval covers Foundayo for adults with a body mass index (BMI) of 30 or higher, as well as those with a BMI of 27–30 who have at least one weight-related condition. It is also authorized for patients with type 2 diabetes that is not adequately controlled. The once-daily tablet starts at a dose of 0.8 mg and can be increased up to 17.2 mg, with no food or water restrictions. Julian Beach, executive director for healthcare quality and access at the MHRA, expressed satisfaction at being the first European regulator to approve the tablet, and the agency will continue monitoring its safety and efficacy.
NHS access now becomes the pivotal next step. The National Institute for Health and Care Excellence (NICE) is expected to publish its appraisal on November 18, which will determine whether Foundayo is recommended for use within the NHS and for which patient groups. Even a positive recommendation could leave questions about rollout timing and commercial terms unresolved.
Lilly faces stiff competition in the oral obesity market, particularly from Novo Nordisk (NYSE: NVO), whose oral Wegovy has already established a foothold. Novo reported that approximately 300,000 patients in the UK had taken its pill within three weeks of its launch, and it projects around 1.5 million users worldwide. With over 20 million UK adults classified as obese, the market potential is immense, but the private sector is already concentrated, with the top 20 providers holding more than 75% of the market.
Wall Street analysts have responded positively to Lilly's recent performance. Last week, several firms raised their price targets, including Truist, Goldman Sachs, BMO Capital, and Morgan Stanley, with new targets ranging from $1,367 to $1,419. The consensus rating remains Overweight, with a median price target of $1,371.50, reflecting a roughly 12% premium to Monday's closing price. However, price forecasts vary widely, from $850 to $1,680.
Looking ahead, Lilly's success in the UK will depend on securing NHS reimbursement and competing effectively with Novo's established oral product. Gastrointestinal side effects and ongoing safety surveillance could also influence adoption rates. A slow private rollout or restrictive NICE guidelines would temper European revenue expectations. Nevertheless, the approval marks a strategic win for Lilly as it seeks to expand its portfolio beyond injectables and capture a larger share of the growing weight-management market.
